<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873650</url>
  </required_header>
  <id_info>
    <org_study_id>CDRB436A2107</org_study_id>
    <nct_id>NCT02873650</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment</brief_title>
  <official_title>A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral&#xD;
      dose in subjects with moderate and severe hepatic impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to continued enrolment difficulties.&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2016</start_date>
  <completion_date type="Actual">April 8, 2019</completion_date>
  <primary_completion_date type="Actual">October 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open-label, parallel group</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUClast)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUFinf)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic drug clearance (CL/F)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate (Lambda_z)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>Predose through 96 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal lab values related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal blood pressure related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal pulse rate related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal respiratory rate related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal body temperature related to study drug</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in electrocardiogram (ECG)</measure>
    <time_frame>Time of study drug administration through 30 days postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1 - Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2-Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3-Severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabrafenib</intervention_name>
    <description>Single dose of 100 mg dabrafenib on Day 1</description>
    <arm_group_label>Group 1 - Control group</arm_group_label>
    <arm_group_label>Group 2-Moderate hepatic impairment</arm_group_label>
    <arm_group_label>Group 3-Severe hepatic impairment</arm_group_label>
    <other_name>DRB436</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (for all subjects)&#xD;
&#xD;
          -  Male and/or female subjects 18-75 years of age&#xD;
&#xD;
          -  Females must be of non-childbearing potential . All non-postmenopausal females must&#xD;
             have a confirmed negative serum pregnancy&#xD;
&#xD;
          -  Subjects in good health condition as determined by no clinically significant findings&#xD;
             from medical history and physical examination.&#xD;
&#xD;
          -  Body mass index (BMI) between ≥18.0 and ≤38.0 kg/m2, with body weight ≥ 50 kg and no&#xD;
             more than 140 kg&#xD;
&#xD;
          -  Laboratory values must be within normal limits (correction allowed) or considered&#xD;
             clinically insignificant&#xD;
&#xD;
          -  Do not participate in any other clinical trials with a BRAF or other RAF inhibitors&#xD;
&#xD;
        Additional inclusion criteria for patients with normal hepatic function (Control group):&#xD;
&#xD;
          -  Absence of clinically significant deviation from normal in medical history, physical&#xD;
             examination, vital signs, electrocardiograms and clinical laboratory determinations.&#xD;
&#xD;
          -  Must match to at least one hepatic impairment subject by age, gender and bodyweight&#xD;
&#xD;
        Additional inclusion criteria for hepatic impaired subjects:&#xD;
&#xD;
          -  Confirmed hepatic disease&#xD;
&#xD;
          -  Stable Child-Pugh status within 28 days prior to dosing.&#xD;
&#xD;
        Exclusion criteria for all subjects&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 weeks prior to dosing&#xD;
&#xD;
          -  Significant acute illness within the two weeks prior to dosing&#xD;
&#xD;
          -  History of immunodeficiency diseases, including a positive HIV&#xD;
&#xD;
          -  History of malignancy of any organ system, treated or untreated, within 5 years&#xD;
&#xD;
          -  Any prior history of keratoacanthoma and/or cutaneous squamous cell carcinoma&#xD;
&#xD;
          -  A known diagnosis of any of the RASopathies, such as NF-1, Noonan syndrome, or related&#xD;
             conditions.&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 6 months prior to dosing&#xD;
&#xD;
          -  Smoking: urine cotinine levels below 500 ng/mL on Day -1.&#xD;
&#xD;
          -  Use of drugs known to affect CYP3A4 and/or CYP2C8 including both (strong or moderate)&#xD;
             inhibitors and inducers, within 7 days prior to dosing&#xD;
&#xD;
          -  Administration of medications that prolong the QT interval within 4 weeks prior to&#xD;
             dosing and until EOT.&#xD;
&#xD;
          -  History or current diagnosis of cardiac disease indicating significant risk of safety&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of drugs.&#xD;
&#xD;
        Additional exclusion criteria for healthy subjects (control group):&#xD;
&#xD;
          -  Clinical evidence of liver disease or liver injury&#xD;
&#xD;
          -  History or presence of renal impairment as indicated by abnormal creatinine or BUN&#xD;
             values&#xD;
&#xD;
          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody&#xD;
&#xD;
        Additional exclusion criteria for subjects with hepatic impairment:&#xD;
&#xD;
          -  Alcohol or drug abuse within one month prior to dosing or evidence of such&#xD;
&#xD;
          -  History of liver transplantation at any time in the past and is on immunosuppressant&#xD;
             therapy.&#xD;
&#xD;
          -  Encephalopathy Grade 3 or worse within 28 days of dosing.&#xD;
&#xD;
          -  History of surgical portosystemic shunt.&#xD;
&#xD;
          -  Life expectancy ≤3 months&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American Institute of Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants LLC</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates Oncology</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17618</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic impairment</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Clinical pharmacology study</keyword>
  <keyword>DRB436</keyword>
  <keyword>dabrafenib</keyword>
  <keyword>normal hepatic function</keyword>
  <keyword>impaired hepatic function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

